Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Obama’s FY 2015 Budget Is A Non-Starter, But Is It Still Bad For FDA?

Executive Summary

Agency advocates may face stronger headwinds in their efforts to boost FDA funding after presidential budget request comes in nearly flat.

You may also be interested in...



FDA Winding Down White Oak Construction; Outside Rents Going Up

President Obama’s budget requests less headquarters consolidation funding in FY 2015 as CBER announces it will move staff to the campus between May and July.

FDA Secure Supply Chain Pilot Draws Small Group, But Could Serve Globalization Goals

Agency planned for up to 100 participants in program allowing expedited entry of some imports, but only approved 13.

Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says

Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS055981

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel